All In Biotech

Drug Trial Radar · NCT02106494

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 942 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

942

Actual

Start

Mar 2014

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Heron TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 87 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (\> 24-120 hours) complete response (CR) rate (defined as no emesis and no use of rescue medications) in subjects receiving highly emetogenic chemotherapy (HEC) as defined by the 2011 ASCO CINV guidelines

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

  • APF530Drug

  • OndansetronDrug

  • Ondansetron placeboDrug

  • APF530 placeboDrug

  • FosaprepitantDrug

  • DexamethasoneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Delayed Phase Complete Response (CR) RateTime frame: 24 - 120 Hours

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC-HAL

    Phoenix, Arizona

  • The Oncology Institute of Hope and Innovation

    Downey, California

  • Compassionate Cancer Medical Center

    Riverside, California

  • Northern Indiana Research

    Mishawaka, Indiana

  • Northern Indiana Research

    South Bend, Indiana

  • North Shore Oncology

    East Setauket, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.